Drug intelligence / Profile preview

DCB-AD1

Development stage: Phase 2
Lead developer: Development Center for Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

DCB-AD1 is a small molecule drug developed by the Development Center for Biotechnology. It has been investigated in a double-blind, randomized, placebo-controlled Phase 2 clinical trial for the treatment of mild to moderate Alzheimer's disease. The study aimed to evaluate its efficacy and safety over 24 weeks. While detailed mechanism of action information is not provided in available sources, the trial's design and context suggest it targets nervous system diseases, specifically Alzheimer's disease[1]. The study also references "Fo-ti," which may indicate that DCB-AD1 contains or is related to extracts from Fo-ti (Polygonum multiflorum), a traditional herbal medicine sometimes studied for neuroprotective effects[1].

Beyond the preview

Go deeper on DCB-AD1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCB-AD1.

Explore the full profile